New PET scans reveal how experimental drug reshapes lung vessels in PAH
NCT ID NCT07357974
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study will use special PET/CT scans to see how the experimental drug sotatercept affects blood vessel remodeling in the lungs and heart of people with pulmonary arterial hypertension (PAH). About 15 adults with PAH will receive sotatercept and have imaging at the start and after 24 weeks. The goal is to measure changes in fibroblast activity and lung blood flow, not to treat symptoms directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chu Brest
Brest, Finistere, 29200, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an inhaled therapy replace a daily pill for PAH?
- Can a Real-World registry improve how treprostinil is used for PAH?
- Which PAH treatment strategy works better: adding a third drug or increasing the dose?
- Lung patients may soon do rehab from home via app
- Which drug is best for pulmonary hypertensive crisis? new trial aims to find out
- New PAH drug IKT-001 moves to Long-Term safety check